KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2016 - 2025)

Rigel Pharmaceuticals has reported Accumulated Expenses over the past 16 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $11.9 million for Q4 2025, up 17.51% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (up 17.51% YoY), and the annual figure for FY2025 was $11.9 million, up 17.51%.
  • Accumulated Expenses for Q4 2025 was $11.9 million at Rigel Pharmaceuticals, up from $10.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RIGL hit a ceiling of $11.9 million in Q4 2025 and a floor of $5.2 million in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $7.9 million (2024), compared with a mean of $8.1 million.
  • Biggest five-year swings in Accumulated Expenses: fell 17.06% in 2022 and later rose 27.02% in 2025.
  • Rigel Pharmaceuticals' Accumulated Expenses stood at $10.7 million in 2021, then dropped by 17.06% to $8.9 million in 2022, then fell by 2.14% to $8.7 million in 2023, then rose by 16.86% to $10.1 million in 2024, then increased by 17.51% to $11.9 million in 2025.
  • The last three reported values for Accumulated Expenses were $11.9 million (Q4 2025), $10.1 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.